Screening visit | • Age, sex, target weight, duration on dialysis, cause of end-stage kidney disease, vascular access type |
• Serum calcium, phosphate, parathyroid hormone, Kt/V, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D | |
• Medication use | |
• GODIN leisure-time activity questionnaire | |
• DASI aerobic capacity questionnaire | |
Baseline study visit | • Serum calcium, phosphate, parathyroid hormone, Kt/V, 25OHD level, 1,25-dihydroxy vitamin D level, catecholamines |
• Renin, aldosterone, angiotensin II | |
• Delivered dose of dialysis (Kt/V) | |
• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters | |
Study visits every 6 weeks up to 24 weeks | • Serum calcium, serum phosphate, parathyroid hormone, 25OHD, 1,25-dihydroxy-vitamin D, catecholamines |
• Renin, aldosterone, angiotensin II | |
• Delivered dose of dialysis (Kt/V) | |
• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters |